Facility Decision Makers

Insightful data analytics with a partner whose foresight and specialized expertise support your program in making critical decisions around cost management, census improvement and treatment program outcomes.

Medical Professionals

Decision support tools in addiction treatment diagnostics keeping you at the forefront of clinical excellence to enhance patient outcomes and reduce healthcare spend.

Patients

Laboratory testing to support you in better understanding how diagnostics is important to maximizing your recovery and helping your healthcare provider make clinically actionable, and personalized decisions for your treatment.

Specialty Partners for Specialty Providers.

Addiction treatment has an uncompromising demand for specialized expertise—from knowing which newly popularized drugs should be added to the screening process, to providing the highest quality results rapidly. As specialists, we strive to keep our partners at the forefront of clinical excellence so they can deliver the best outcomes for their clients.

CORE PRODUCT LINE

SpectraUDT

Treatment Focused Menu
28 Drug Classes/190 Drugs
41 Fentanyl Analogs
3 mL Min Sample Vol
24 Hr Results TAT

LEARN MORE

SpectraPGx

Pain and Psych Panel
A personalized medical approach that enables our partners to provide their clients with the appropriate dosages of the proper medications early in the treatment process.
MAT + PGx
Reduce ADR’s

LEARN MORE

SpectraDX

Comprehensive Medical Screening
Hematology
Chemistry
Hormone Testing
Urinalysis
Infectious Disease

LEARN MORE

Purpose Built to Support Addiction Treatment

New and Emerging Drug Trends
Comprehensive Menu from Detox to Recovery
Consistent 24hr TAT
Pioneering Substance Use Disorder Diagnostics Research
Cutting Edge Technology

Keeping you at the Forefront of Clinical Excellence

27% of all specimens from Substance Abuse Treatment Centers were positive for nonprescribed Fentanyl. In addition, 83% of positive heroin samples also contained fentanyl.

Drug Misuse Report

2018

Medical costs for treating patients with chronic medical and comorbid mental health/substance use disorder (MH/SUD) conditions are two to three times higher on average than compared to the costs for those who don’t have MH/SUD conditions.

Potential Economic Impact of Integrated Medical-Behavioral Healthcare

Feb 12, 2018

Fewer than half of patients with depression respond to their 1^st prescribed medication and overall treatment failure rates exceed 50%

AMJ Psych.

2006; 163:28-40

80% of patients who have failed at least one medication are currently taking a genetically sub-optimal medication

Discovery Med.

2013; 16(89):219-227

Addiction Labs is a subsidiary of American Addiction Centers, Inc. Learn more about what this means here.